RDPT.F Stock Overview

Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. More details

RDPT.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 98.1% below our estimate of its fair value

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Does not have meaningful revenue (A$2M)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Radiopharm Theranostics Limited Competitors

Surrozen

NasdaqCM:SRZN

US$41.6m

Marker Therapeutics

NasdaqCM:MRKR

US$25.5m

Pluri

NasdaqCM:PLUR

US$24.7m

Palatin Technologies

NYSEAM:PTN

US$23.5m

Price History & Performance

Summary of share price highs, lows and changes for Radiopharm Theranostics
Historical stock prices
Current Share Price	AU$0.30
52 Week High	AU$0.30
52 Week Low	AU$0.0008
Beta	0.85
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	233.33%

Recent updates

Shareholder Returns

	RDPT.F	US Biotechs	US Market
7D	0%	-0.1%	-0.5%
1Y	n/a	-6.4%	23.2%

Return vs Industry: Insufficient data to determine how RDPT.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how RDPT.F performed against the US Market.

Price Volatility

Is RDPT.F's price volatile compared to industry and market?
RDPT.F volatility
RDPT.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: RDPT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RDPT.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2021	n/a	Riccardo Canevari	www.radiopharmtheranostics.com

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.

Radiopharm Theranostics Limited Fundamentals Summary

How do Radiopharm Theranostics's earnings and revenue compare to its market cap?
RDPT.F fundamental statistics
Market cap	US$47.06m
Earnings (TTM)	-US$29.67m
Revenue (TTM)	US$1.21m

38.8x

P/S Ratio

-1.6x

P/E Ratio

Is RDPT.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RDPT.F income statement (TTM)
Revenue	AU$1.96m
Cost of Revenue	AU$21.61m
Gross Profit	-AU$19.65m
Other Expenses	AU$28.30m
Earnings	-AU$47.95m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.022
Gross Margin	-1,003.25%
Net Profit Margin	-2,448.23%
Debt/Equity Ratio	0%

How did RDPT.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 18:43
End of Day Share Price	2024/10/22 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Radiopharm Theranostics Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Hunter Diamond	Diamond Equity Research LLC
Justin Walsh	JonesTrading Institutional Services, LLC